Close Menu
  • News
  • Stocks
  • Bonds
  • Commodities
  • Collectables
    • Art
    • Classic Cars
    • Whiskey
    • Wine
  • Trading
  • Alternative Investment
  • Markets
  • More
    • Economy
    • Money
    • Business
    • Personal Finance
    • Investing
    • Financial Planning
    • ETFs
    • Equities
    • Funds

Subscribe to Updates

Get the latest markets and assets news and updates directly to your inbox.

Trending Now

Basquiat Estate Releases New Print in Edition of 60, Signed by the Artist’s Sisters

October 29, 2025

5m @ 13.1g/t Gold Intersected within 20m Mineralised Zone in First Drill Hole to Test New Target at Titan East

October 29, 2025

Exhibition at David Zwirner Gallery Hopes to Raise $350,000 for New York’s Ali Forney Center

October 29, 2025
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram
The Asset ObserverThe Asset Observer
Newsletter
LIVE MARKET DATA
  • News
  • Stocks
  • Bonds
  • Commodities
  • Collectables
    • Art
    • Classic Cars
    • Whiskey
    • Wine
  • Trading
  • Alternative Investment
  • Markets
  • More
    • Economy
    • Money
    • Business
    • Personal Finance
    • Investing
    • Financial Planning
    • ETFs
    • Equities
    • Funds
The Asset ObserverThe Asset Observer
Home»Stocks
Stocks

Eli Lilly’s Alzheimer’s drug wins FDA approval

Jon RobertsBy Jon RobertsJuly 2, 2024
Share
Facebook Twitter LinkedIn Pinterest Email
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Home builders are struggling, and it’s not just because new houses aren’t affordable

How a few new crypto ETFs slipped through the cracks of the government shutdown

Here’s why Oreo maker Mondelez gave Wall Street a cloudier outlook for the year

The ‘Magnificent Seven’ have never been this important to the stock market — and a big test lies ahead

Opinion: These bargain stocks haven’t been so overlooked since the Great Depression. Time to add some to your 401(k)?

Microsoft’s stock rises as new OpenAI partnership comes as a relief to investors

Palantir has a high bar to clear this earnings season. Can it deliver again?

Meta’s earnings are on deck. These are the four biggest numbers to watch.

Opinion: Here’s how the smart money is buying gold, now that it’s likely peaked for the year

Recent Posts
  • Basquiat Estate Releases New Print in Edition of 60, Signed by the Artist’s Sisters
  • 5m @ 13.1g/t Gold Intersected within 20m Mineralised Zone in First Drill Hole to Test New Target at Titan East
  • Exhibition at David Zwirner Gallery Hopes to Raise $350,000 for New York’s Ali Forney Center
  • Copper Prices Surge on US-China Deal Optimism, Tight Supply Adds to Rally
  • Met Museum Sued Again by Jewish Heirs Over Van Gogh Painting Sold to Greek Collectors

Subscribe to Newsletter

Get the latest markets and assets news and updates directly to your inbox.

Editors Picks

5m @ 13.1g/t Gold Intersected within 20m Mineralised Zone in First Drill Hole to Test New Target at Titan East

October 29, 2025

Exhibition at David Zwirner Gallery Hopes to Raise $350,000 for New York’s Ali Forney Center

October 29, 2025

Copper Prices Surge on US-China Deal Optimism, Tight Supply Adds to Rally

October 29, 2025

Met Museum Sued Again by Jewish Heirs Over Van Gogh Painting Sold to Greek Collectors

October 29, 2025

Nextech3D.ai Reports Milestone YTD Revenue Growth for AI Matchmaking in 2025 with a 95% Gross Margin

October 29, 2025
Facebook X (Twitter) Instagram
© 2025 The Asset Observer. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Press Release
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.